Press release
Pancreatic Cancer Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis | ERYtech Pharma, Jiangsu HengRui Medicine Co., Ltd., FibroGen, Novartis AG, AB Science, Eleison Pha
Pancreatic Cancer Pipeline constitutes 290+ key companies continuously working towards developing 300+ Pancreatic Cancer treatment therapies, analyzes DelveInsight.Pancreatic Cancer Overview:
Pancreatic cancer occurs when malignant cells develop in the pancreas, an organ located behind the stomach. It typically originates from pancreatic intraepithelial neoplasia (PanIN), a common pre-cancerous lesion, but can also arise from larger precursor lesions like intraductal papillary mucinous neoplasms (IPMNs) and mucinous cystic neoplasms. The cancer is characterized by abnormal signaling that promotes the proliferation, migration, invasion, and metastasis of cancer cells.
In addition, pancreatic cancer involves metabolic changes and resistance to growth-inhibiting signals. One example of this is the abnormal TGFβ signaling pathway. Although TGFβ usually acts as a tumor suppressor, its increased expression in pancreatic cancer contributes to tumor progression by stimulating growth and metastasis. TGFβ can also promote cancer cell proliferation through non-canonical signaling pathways, involving MAPK phosphorylation, Src, AKT, and WNT7B, which help drive cancer development.
Request for a detailed insights report on Pancreatic Cancer pipeline insights @ https://www.delveinsight.com/report-store/pancreatic-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
"Pancreatic Cancer Pipeline Insight 2024" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Pancreatic Cancer Therapeutics Market.
Key Takeaways from the Pancreatic Cancer Pipeline Report
DelveInsight's Pancreatic Cancer pipeline report depicts a robust space with 290+ active players working to develop 300+ pipeline therapies for Pancreatic Cancer treatment.
In December 2024, Zai Lab Limited and Novocure announced that the Phase 3 PANOVA-3 trial successfully met its primary endpoint, demonstrating a statistically significant improvement in median overall survival (mOS) compared to the control group. The trial evaluated the combination of Tumor Treating Fields (TTFields) therapy with gemcitabine and nab-paclitaxel as a first-line treatment for unresectable, locally advanced pancreatic adenocarcinoma.
Key Pancreatic Cancer companies such as ERYtech Pharma, Jiangsu HengRui Medicine Co., Ltd., FibroGen, Novartis AG, AB Science, Eleison Pharmaceuticals, Cornerstone Pharmaceuticals, Panbela Therapeutics, Taiho Pharmaceutical Co., Ltd., Rain Oncology, Redx Pharma Plc, Eli Lilly and Company, Jazz Pharmaceuticals, Immodulon Therapeutics Ltd, GSK, Merck Sharp & Dohme LLC, Roche, Helsinn Healthcare SA, DEKA Biosciences, Senhwa Biosciences, Cue Biopharma, Carisma Therapeutics Inc, ChemoCentryx, Boehringer Ingelheim, Bicara Therapeutics, Arcus Biosciences, Mainline Biosciences, Beijing Imunopharm Technology Co., Ltd., TriSalus Life Sciences, Ono Pharmaceutical, Exelixis, Wellmaker Bio, Pionyr Immunotherapeutics, Ability Pharmaceuticals SL, A2 Biotherapeutics, Klus Pharma Inc., Nelum Corp, Crystal Genomics Inc., Elicio Therapeutics, Turning Point Therapeutics, Immuneering Corporation, pHion Therapeutics Ltd., AC BioScience, TheraVectys, Opna Bio, Cytuvax, Eureka Therapeutics, and others are evaluating new drugs for Pancreatic Cancer to improve the treatment landscape.
Promising Pancreatic Cancer pipeline therapies in various stages of development include Pamrevlumab, Devimistat, Masitinib, SBP-101, TAS-102, RAIN-32, IMX-110, and others.
Pancreatic Cancer Pipeline Analysis
The report provides insights into:
The report provides detailed insights into the key companies that are developing therapies in the Pancreatic Cancer Market.
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Pancreatic Cancer treatment.
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Pancreatic Cancer market.
Download our free sample page report on Pancreatic Cancer pipeline insights @ https://www.delveinsight.com/sample-request/pancreatic-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Pancreatic Cancer Emerging Drugs
Pamrevlumab: FibroGen
Devimistat: Cornerstone Pharmaceuticals
Masitinib: AB Science
SBP-101: Panbela Therapeutics
TAS-102: Taiho Pharmaceutical Co., Ltd.
RAIN-32: Rain Oncology
IMX-110: Immix Biopharma
Pancreatic Cancer Companies
More than 290 major companies are involved in developing treatments for pancreatic cancer. FibroGen is one of these companies, with drug candidates for pancreatic cancer currently in the advanced Phase III stage.
DelveInsight's report covers around 300+ products under different phases of clinical development like
Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Pancreatic Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Intravenous
Subcutaneous
Oral
Intramuscular
Pancreatic Cancer Products have been categorized under various Molecule types such as
Monoclonal antibody
Small molecule
Peptide
Download Sample Pages to Get an in-depth Assessment of the Emerging Pancreatic Cancer Therapies and Key Companies: Pancreatic Cancer Clinical Trials and advancements @ https://www.delveinsight.com/report-store/pancreatic-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Pancreatic Cancer Pipeline Therapeutic Assessment
• Pancreatic Cancer Assessment by Product Type
• Pancreatic Cancer By Stage
• Pancreatic Cancer Assessment by Route of Administration
• Pancreatic Cancer Assessment by Molecule Type
Download Pancreatic Cancer Sample report to know in detail about the Pancreatic Cancer treatment market @ Pancreatic Cancer Therapeutic Assessment @ https://www.delveinsight.com/sample-request/pancreatic-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Table of Content
1. Report Introduction
2. Executive Summary
3. Pancreatic Cancer Current Treatment Patterns
4. Pancreatic Cancer - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Pancreatic Cancer Late-Stage Products (Phase-III)
7. Pancreatic Cancer Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Pancreatic Cancer Discontinued Products
13. Pancreatic Cancer Product Profiles
14. Pancreatic Cancer Key Companies
15. Pancreatic Cancer Key Products
16. Dormant and Discontinued Products
17. Pancreatic Cancer Unmet Needs
18. Pancreatic Cancer Future Perspectives
19. Pancreatic Cancer Analyst Review
20. Appendix
21. Report Methodology
Request the Sample PDF to Get Detailed Insights About the Pancreatic Cancer Pipeline Reports Offerings: https://www.delveinsight.com/report-store/pancreatic-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Contact Info:
Kritika Rehani
krehani@delveinsight.com
info@delveinsight.com
+14699457679
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Pancreatic Cancer Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis | ERYtech Pharma, Jiangsu HengRui Medicine Co., Ltd., FibroGen, Novartis AG, AB Science, Eleison Pha here
News-ID: 3816584 • Views: …
More Releases from DelveInsight Business Research LLP

Cutaneous Lupus Erythematosus Treatment Market Size Report 2034 | Horizon Therap …
DelveInsight's "Cutaneous Lupus Erythematosus Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of the Cutaneous Lupus Erythematosus, historical and forecasted epidemiology as well as the Cutaneous Lupus Erythematosus market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Key Takeaways from the Cutaneous Lupus Erythematosus Market Research Report
• The increase in Cutaneous Lupus Erythematosus Market Size is a direct consequence of the…

Congestive Heart Failure Treatment Market Size Report 2032 | Novartis, Boehringe …
DelveInsight's "Congestive Heart Failure Market Insights, Epidemiology, and Market Forecast - 2032" report delivers an in-depth understanding of Congestive Heart Failure, historical and forecasted epidemiology as well as the Congestive Heart Failure market trends in the United States, EU4 (Germany, Spain, Italy, France) and the United Kingdom, and Japan.
Key Takeaways from the Congestive Heart Failure Market Research Report
• The increase in Congestive Heart Failure Market Size is a direct consequence…

Chronic Spontaneous Urticaria Therapeutics Market Size Report 2032 | Novartis, S …
DelveInsight's "Chronic Spontaneous Urticaria Market Insights, Epidemiology, and Market Forecast - 2032" report delivers an in-depth understanding of chronic spontaneous Urticaria, historical and forecasted epidemiology, as well as the chronic spontaneous Urticaria market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
Key Takeaways from the Chronic Spontaneous Urticaria Market Research Report
• The increase in Chronic Spontaneous Urticaria Market Size is a direct…

Chronic Rhinosinusitis with Nasal Polyps Treatment Market Size Report 2032 | Ast …
DelveInsight's 'Chronic Rhinosinusitis with Nasal Polyps Market Insights, Epidemiology, and Market Forecast-2032' report deliver an in-depth understanding of the Chronic Rhinosinusitis with Nasal Polyps, historical and forecasted epidemiology as well as the market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
Key Takeaways from the Chronic Rhinosinusitis with Nasal Polyps Market Report
• The increase in Chronic Rhinosinusitis with Nasal Polyps Market Size is a…
More Releases for Pancreatic
Pancreatic Cancer Therapy Market: Rise in Number of Patients Suffering with Panc …
Pancreatic cancer is one of the aggressive cancers that originate in the tissues of the pancreas and rapidly spreads to the nearby organs. Pancreatic cancer is the 12th most commonly occurring cancer in the world. According to the American Cancer Society, ~55,440 patients in the US are expected to be diagnosed with pancreatic cancer in 2018. Moreover, the ACS also reports that pancreatic cancer is the third leading cause of…
Pancreatic Cancer Treatment
Pancreatic Cancer Treatment Market describes its growth, size, share, Forecast and trends to 2025
Pancreatic Cancer Treatment Market Production and Demand Analysis 2019 to 2025
Pancreatic Cancer Treatment Market 2019 Manufacturing Analysis and Development Forecast 2025
Pancreatic Cancer Treatment Market 2019: Recent Study Including Growth Factors, Regional Drivers, Forecast 2025
Pancreatic Market to Insight By 2025: Top Key Vendors
Pancreatic cancer arises when cells in the pancreas, a glandular organ behind the stomach, begin to…
Exocrine Pancreatic Insufficiency (EPI) Therapeutics- Pipeline Analysis
Exocrine pancreatic insufficiency (EPI) is the inability of pancreas to produce enough enzymes for the proper breakdown and absorption of nutrients. The common causes of EPI are damage to pancreas, inflammation of pancreas, pancreatic surgery, and inherited disorders like Crohn’s disease and celiac disease.
Download the sample report at: https://www.pharmaproff.com/request-sample/1024
Some symptoms observed during EPI are pain or tenderness in belly, bad-smelling bowel movements, gas, diarrhea and feeling of fullness. EPI…
Pancreatic Cancer Pipeline Review H1 2019
Pancreatic Cancer - Pipeline Review, H1 2017
Summary
Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Pancreatic Cancer - Pipeline Review, H1 2017, provides an overview of the Pancreatic Cancer (Oncology) pipeline landscape.
Pancreatic cancer is a disease in which malignant (cancer) cells are found in the tissues of the pancreas. This is also called exocrine cancer. Signs and symptoms include upper abdominal pain that may radiate to back, yellowing of skin and…
Pancreatic Cancer Drug Pipeline Analysis
“Pancreatic Cancer Drug Pipeline Analysis” by PNS Pharma gives comprehensive insight on the various drug profiles being developed for the treatment of Pancreatic Cancer. Research report covers all the ongoing drug development in various phases. Each drug profiles include detailed information like: Originator, Owner, Collaborator, Technology Provider, Licensee, Development Phase, Development Indications, Mechanism of Action, Chemical Formula, Country of Development and detailed analysis on the development process. Insight for each…
Exocrine Pancreatic Insufficiency Market 2013
Transparency Market Research has published a new market report titled, “Exocrine Pancreatic Insufficiency Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2013 – 2023.” According to the report, the exocrine pancreatic insufficiency market is anticipated to expand at a CAGR of 8.3% from 2015 to 2023 to reach US$2.85 Bn by 2023.
Browse the full Exocrine Pancreatic Insufficiency Market – (Therapeutic – Pancreatic Enzyme Replacement Therapy (Creon, Zenpep,…